UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000051104
Receipt number R000058278
Scientific Title Impact of Hypoxia Inducible Factor Prolyl Hydoxylase inhibitors on diabetic macular edema and diabetic retinopathy, multicenter study
Date of disclosure of the study information 2023/05/19
Last modified on 2023/05/19 10:30:27

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Impact of HIF-PH inhibitors on diabetic macular edema and diabetic retinopathy, multicenter study

Acronym

Impact of HIF-PH inhibitors on diabetic macular edema, multicenter study

Scientific Title

Impact of Hypoxia Inducible Factor Prolyl Hydoxylase inhibitors on diabetic macular edema and diabetic retinopathy, multicenter study

Scientific Title:Acronym

Impact of HIF-PH inhibitors on DME

Region

Japan


Condition

Condition

Renal anemia, diabetic retinopathy, diabetic macular edema

Classification by specialty

Medicine in general Endocrinology and Metabolism Nephrology
Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare and evaluate retinal optical coherence tomography (OCT) findings including central retinal thickness, visual acuity, diabetic macular edema, and diabetic retinopathy before and after treatment in diabetic patients initiating HIF-PH inhibitor therapy due to renal anemia. A multicenter prospective study will be conducted to determine whether HIF-PH inhibitor treatment exacerbates diabetic macular edema.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

OCT findings including retinal thickness.
visual acuity.
Hemoglobin and other blood tests to assess the degree of anemai.

Key secondary outcomes

The progression of diabetic malular edema and retinopathy (Fundus photography or observation)


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit

100 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Patients with diabetes mellitus who visited the ophthalmologist from the date of approval by the head of the research institution to March 31, 2028
2. Patients with visual acuity and OCT imaging data before and after the start of HIF-PH administration

Key exclusion criteria

1.Blind in both eyes
2. Inability to perform OCT examination
3. Other patients who are judged as unfit by the ophthalmologist

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Hideyuki
Middle name
Last name Oshima

Organization

university of Fukui Hospital

Division name

Ophthalmology

Zip code

9101193

Address

23-3, matcuoka shimoaituki, eiheiji-cho, yoshida-gun, Fukui

TEL

0776-61-8403

Email

osm@g.u-fukui.ac.jp


Public contact

Name of contact person

1st name Hideyuki
Middle name
Last name Oshima

Organization

university of Fukui Hospital

Division name

Ophthalmology

Zip code

9101193

Address

23-3, matcuoka shimoaituki, eiheiji-cho, yoshida-gun, Fukui

TEL

776618403

Homepage URL


Email

osm@g.u-fukui.ac.jp


Sponsor or person

Institute

University of Fukui

Institute

Department

Personal name



Funding Source

Organization

self-funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Fukui Red Cross Hospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization

university of Fukui Hospital

Address

23-3, matcuoka shimoaituki, eiheiji-cho, yoshida-gun, Fukui

Tel

776618403

Email

takamurayoshihiro@gmail.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2023 Year 05 Month 19 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2023 Year 04 Month 23 Day

Date of IRB

2023 Year 04 Month 26 Day

Anticipated trial start date

2023 Year 04 Month 27 Day

Last follow-up date

2028 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

nothing particular


Management information

Registered date

2023 Year 05 Month 19 Day

Last modified on

2023 Year 05 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000058278


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name